Phosphoglycerate dehydrogenase (PHGDH) is involved in the early steps of L-serine synthesis in animal cells.In addition to D-serine, which is a significant agonist of the N-methyl-D-aspartate (NMDA) receptor, L-serine is an essential amino acid because it functions as a precursor to many other essential metabolites. The de novo serine biosynthetic pathway's first and only rate-limiting enzyme, PHGDH, catalyzes the oxidation of 3-PG produced during glycolysis to 3-phosphohydroxypyruvate (3-PHP).In a family with congenital microcephaly, psychomotor retardation, and other symptoms, mutations in the PHGDH gene have been discovered. Overexpression-related increases in PGDH levels are linked to a variety of cancers. Extracellular L-serine cannot support tumor cell proliferation in culture because PGDH is necessary for this process. This has given rise to the theory that the pathway serves a purpose other than supplying L-serine that is connected to tumor growth.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V5026 | CBR-5884 | 681159-27-3 | CBR-5884 is a novel, potent, and selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50of 33 μM and with anticancer activities. |
|
V84711 | PHGDH-IN-4 | 2132969-16-3 | |
|
V87675 | PHGDH-IN-5 | 17402-86-7 | PHGDH-IN-5 (Compound B12) is a PHGDH covalent inhibitor with IC50 of 0.29 μM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
